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Contribution of PSA density in the prediction
of prostate cancer in patients with PSA values between
2.6 and 10.0 ng/ml*
Contribuição da densidade do PSA para predizer o câncer da próstata em pacientes com valores de PSA
entre 2,6 e 10,0 ng/ml
Hugo Alexandre Sócrates de Castro1, Wagner Iared2, David Carlos Shigueoka3, José Eduardo
Mourão4, Sérgio Ajzen5
Objective: To study the profile of patients with PSA level between 2.6 and 10.0 ng/ml and submitted to prostate biopsy,
determining possible patterns that might lead to a reduction of unnecessary biopsies. Materials and Methods: In the
period from 2007 to 2009, a cross-sectional study was developed with 1,282 patients with PSA levels between 2.6
and 10.0 ng/ml, and submitted to prostate biopsy. Results: Cancer prevalence was 28.6%. On average, the patients
with positive biopsies were older, with higher PSA levels and density, and smaller prostate volume as compared with
the patients with negative biopsies. In the analysis of PSA density, the cancer patients averaged 0.31 ng/ml/cc, while
patients with negative results averaged 0.10 ng/ml/cc. Utilizing a cutoff value of 0.15 ng/ml/cc for PSA density as a
cancer positiveness criterion, the authors obtained sensitivity of 74% and specificity of 70%. The cutoff value should
be reduced to increase the sensitivity. With a cutoff value of 0.09 ng/ml/cc, sensitivity reached 84% (CI 95%: 80–87%),
and specificity, 75% (CI 95%: 72–78%). Conclusion: The systematic use of PSA density as an indicator to proceed
with the investigation of a patient with biopsy could substantially reduce the amount of unnecessary procedures.
Keywords: Prostate; Prostate biopsy; Prostate cancer; PSA density.
Objetivo: Estudar o perfil dos pacientes submetidos a biópsia prostática, determinando possíveis padrões que, asso-
ciados aos níveis de PSA entre 2,6 e 10,0 ng/ml, possam levar a uma diminuição de biópsias desnecessárias. Mate-
riais e Métodos: De 2007 a 2009, foi realizado um estudo transversal com 1.282 indivíduos submetidos a biópsia
prostática e que apresentavam níveis de PSA entre 2,6 e 10,0 ng/ml. Resultados: A prevalência de câncer foi de
28,6%. Pacientes com câncer eram, em média, mais idosos, com valores de PSA e densidade de PSA mais altos e
menor volume da próstata. Na análise da densidade de PSA, os pacientes com câncer tiveram média de 0,31 ng/ml/cc,
enquanto nos pacientes com resultado negativo a média foi de 0,10 ng/ml/cc. Utilizando como critério de positividade
para câncer o ponto de corte de densidade de PSA de 0,15 ng/ml/cc, obtivemos especificidade de 74% e sensibilidade
de 70%. Para aumentar a sensibilidade é preciso reduzir o ponto de corte. Com o valor 0,09 ng/ml/cc, obtivemos
sensibilidade de 84% (IC 95%: 80–87%) e especificidade de 75% (IC 95%: 72–78%). Conclusão: O uso sistemático
da densidade de PSA na indicação de prosseguimento da investigação do paciente com biópsia poderia reduzir a
quantidade de procedimentos desnecessários.
Unitermos: Próstata; Biópsia de próstata; Câncer de próstata; Densidade de PSA.
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cer Institute) forecasts 52,350 new cases in
Brazil in 2010(1).
Prostate cancer affects mostly patients
above 50 years of age and preferably occurs
in the prostate peripheral zone. Mortality
rate is relatively low, particularly in early
diagnosed cases(2).
Digital rectal examination and serum
prostate-specific antigen (PSA) test are the
most utilized methods of prostate cancer
screening. The digital rectal examination
presents limitations in case of nonpalpable
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INTRODUCTION
According to the World Health Organi-
zation, prostate cancer is the second most
common cancer in men, being the sixth
most frequent cause of deaths among the
male population worldwide. The Instituto
Nacional de Câncer (INCA) (National Can-
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prostatic lesion (early stages), and when-
ever a change is detected, the differentia-
tion between malignant and benign lesions
is difficult. Serum PSA testing, in clinical
use since 1986, is the most frequently uti-
lized tumor marker for the screening of
prostate cancer. It plays an important role
in the early diagnosis of such cancer, with
a considerable impact on the reduction of
the disease morbidity and mortality(3).
The epithelial cells in the transition
zone are accountable for PSA serum lev-
els and the increase in prostatic volume is
directly related to the increased level of such
antigen. A number of factors may affect the
PSA levels, and should therefore be con-
sidered in the interpretation of tests results.
The most common causes for the increase
in PSA levels are prostatitis, benign pros-
tatic hyperplasia and prostate cancer(4).
The screening by means of PSA testing
is aimed at detecting the highest possible
number of cases. In spite of its high sensi-
tivity, this test has a low specificity for pros-
tate cancer, which means that in order to
achieve acceptable diagnosis rates, many
patients are submitted to unnecessary biop-
sies. There is a doubtful zone traditionally
considered as the PSA range between 4.1
and 10.0 ng/ml within which all patients
are considered to be under suspicion of
prostate cancer. Most recently, such zone
has been expanded to levels between 2.6
and 10.0 ng/ml(5), which further increases
the number of suspected cases. Within this
doubtful zone, PSA testing has a low speci-
ficity, with approximately 75% of the pros-
tate biopsies being negative for neopla-
sia(6). For an improved screening of candi-
dates for such a procedure, new parameters
are being analyzed. Some studies suggest
that among those parameters, PSA density
(PSAD), which is the ratio between the
absolute PSA value and the prostate vol-
ume, might increase the specificity of the
PSA test(7).
The Unit of Interventional Ultrasonog-
raphy of the Department of Imaging Diag-
nosis Department of Universidade Federal
de São Paulo (Unifesp) averagely performs
120 prostate biopsies per month; approxi-
mately 70% of such biopsies are negative
for neoplasia. Taking such data into consid-
eration, and in an attempt to reduce the
number of unnecessary biopsies, the au-
thors have proposed the present study to
analyze the profile of patients with PSA
values between 2.6 and 10.0 ng/ml and
submitted to prostate biopsies, with the
purpose of identifying variables which
might increase the PSA specificity, and thus
avoiding unnecessary procedures.
MATERIALS AND METHODS
In the period between 2007 and 2009,
a cross-sectional study was carried out with
male patients with PSA levels ranging be-
tween 2.6 and 10.0 ng/ml, referred to the
Unit of Interventional Ultrasonography of
Hospital São Paulo to undergo prostate
biopsy.
The patients were evaluated according
to the following parameters: age, prostate
volume, PSA level, anatomopathological
study – whenever positive for cancer, af-
fected zones and Gleason classification for
malignancy.
The patients who signed a Term of Free
and Informed Consent were included in the
study that was duly approved by the Com-
mittee for Ethics in Research of the insti-
tution. Those patients whose PSA levels,
prostate volume or anatomopathological
results could not be evaluated as well as
those who otherwise did not agree in par-
ticipating in the study, were excluded.
The ultrasonography equipment utilized
was an EnVisor model (Philips; Eindhoven,
Netherlands), with a 9 MHz transducer.
The endorectal approach was utilized for
prostate evaluation. The calculation of the
prostate volume was performed by means
of the formula as follows:
AP × CC × LL × 0.523
where: AP is the anteroposterior diameter,
CC is the craniocaudal diameter, and LL is
the latero-lateral diameter (Figure 1).
The PSAD is the result of the division
of PSA by the prostate volume(7).
The biopsies were performed by acquir-
ing 12 fragments from the peripheral zone
with 18 G needles, being two specimens
from each sextant, one lateral and one
medial. The specimens were placed in in-
dividual labeled vials, each one with the
identification of the sextant from which
they were taken, and were separately evalu-
ated by the pathologist. In the cases that
were positive for prostate cancer, the
Gleason grading system for malignancy
was utilized(8,9).
The patient’s age, PSA values and pros-
tate volumes were correlated with the pres-
ence of cancer. In the presence of cancer,
the lesion location and malignancy grade
were also correlated. In addition, the accu-
racy of PSA density in predicting prostate
cancer in patients with PSA levels between
2.6 and 10.0 ng/ml was evaluated.
For comparisons between groups, the
Student’s t test and the non-parametric
Mann-Whitney test were utilized for nor-
mal and non-normal data, respectively.
Figure 1. Transrectal ultrasonography study with volume measurement.
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The capability of PSAD in differentiat-
ing cancer patients from those without the
disease was evaluated by means of ROC
curve, and measurements of sensitivity and
specificity, positive and negative predictive
values (PPV and NPV), as well as positive
and negative likelihood ratios (respectively,
LR+ and LR–).
The adopted significance level was 0.05.
The utilized softwares were SPSS for Win-
dows, version 17.0 and the RevMan 5.20.
RESULTS
From the 1,384 patients recruited in the
period between 2007 and 2009, 102 were
excluded because of the absence of data
regarding prostate volume, PSA levels or
anatomopathological results. Thus 1,282
patients remained in the study.
Among the 1,282 patients submitted to
prostate biopsy, the prevalence of cancer
was 28.6%. The remaining 71.4% pre-
sented negative results for prostate cancer.
Mean patients’ age was 65 years, rang-
ing from 43 to 93 years. The patients group
whose biopsies did not confirm prostate
cancer had a mean age of 64.6 years, while
the group with prostate cancer had a mean
age of 69.6 years (Table 1).
As the prostate volume was evaluated,
the patients with positive results for pros-
tate cancer presented a mean prostate vol-
ume of 41.4 cm3 while for those with nega-
tive results, the mean prostate volume was
56.9 cm3 (Table 2).
In the analysis of PSA levels, the pa-
tients with positive results for prostate can-
cer presented a mean value of 8.9 ng/ml,
while those with negative results presented
a mean value of 6.1 ng/ml. Mean PSA val-
ues for both groups were within the range
of 2.6 to 10.0 ng/ml, which corresponded
to the evaluated doubtful zone.
As the PSA levels were broken-down
into two ranges of incidence, from 2.6 to
4.0 ng/ml and from 4.1 to 10.0 ng/ml, one
observed that in the first one there were 217
patients (17% of the total), 24 (11%) of them
with cancer. In the second range of inci-
dence there were 1,065 patients (83% of the
total), 32.1% of them positive for cancer.
As the PSAD was evaluated, it was
observed that the patients with prostate
cancer presented a mean value of 0.31 ng/
Table 1 Comparison between patients with positive and negative results for prostate cancer, in relation
to age.
Cancer
No
Yes
Age
Mean
64.65
69.63
Median
64.00
69.00
Standard error
0.44
0.64
Minimum
43.00
46.00
Maximum
86.00
93.00
Number
916
336
Student’s t test: p < 0.001.
Table 2 Relationship of the gross prostate volume values with positive and negative results for prostate
cancer.
Cancer
No
Yes
Age
Mean
56.96
41.46
Median
50.48
39.26
Standard error
1.86
1.99
Minimum
15.26
14.03
Maximum
195.89
166.65
Number
916
336
Student’s t test: p < 0.001.
Table 3 Comparison between patients with positive and negative anatomopathological results in rela-
tion to PSA density (ng/ml/cc).
Cancer
No
Yes
Age
Mean
0.10
0.31
Median
0.14
0.30
Standard error
0.01
0.03
Minimum
0.03
0.10
Maximum
1.10
1.20
Number
916
336
Student’s t test: p < 0.001.
Table 4 Areas under the ROC curves for PSA density utilizing the 0.15 ng/ml/cc and 0.09 ng/ml/cc
cutoff points in three age groups.
0.09 ng/ml/cc cutoff point 0.15 ng/ml/cc cutoff point
Age group
Up to 60 years
60 to 70 years
70 years or more
Area under
the ROC curve
0.717
0.800
0.808
CI 95%
[0.643; 0.792]
[0.744; 0.856]
[0.755; 0.862]
Area under
the ROC curve
0.697
0.780
0.797
CI 95%
[0.622; 0.772]
[0.719; 0.841]
[0.742; 0.851]
ml/cc, while those with negative results
presented a mean value of 0.10 ng/ml/cc
(Table 3).
By utilizing the PSAD cutoff point of
0.15 ng/ml/cc as a cancer positivity crite-
rion, as suggested by the literature(7), the
area under the ROC curve was 0.720. For
such value, a specificity of 74% was ob-
tained (CI 95%: 71–77%) and sensitivity
was 70% (CI 95%: 65–74%).
When it comes to cancer detection, one
should minimize the number of false posi-
tive results and prioritize sensitivity. In the
present case, aiming at increasing sensitiv-
ity, it is necessary to reduce the cutoff point.
With the value of 0.09 ng/ml/cc, a sensitiv-
ity of 84% was obtained (CI 95%: 80-87%),
the specificity was 75% (CI 95%: 72–78%)
and the area under the ROC curve was
0.794 (Figure 2). The LR’s were calculated
for the two selected cutoff points. For the
0.15 ng/ml/cc criterion, a LR+ of 2.72 and
a LR– of 0.41 were found. On the other
hand, for the 0.09 ng/ml/cc criterion, the
LR+ and LR– of 3.36 and 0.21 respec-
tively, were found.
In order to evaluate the relation between
the PSAD performance and age in the pre-
diction of prostate cancer, the patients were
divided into three subgroups according to
the distribution tertiles, and the discrimina-
tion power of PSAD was evaluated by
means of the area under the ROC curve. In
all the analyses, the discrimination seemed
to be better in the older patients, however
with no statistical significance (Table 4).
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method for prostate cancer screening. Its
utilization increases the detection of pros-
tate cancer in up to 81% as compared with
digital rectal examination alone(3,4,10). In
cases of increased PSA, it is difficult to dif-
ferentiate cancer from benign prostatic hy-
perplasia, particularly in patients with inter-
mediate levels between 2.6 and 10.0 ng/ml.
In order to optimize the PSA effectiveness
as a diagnostic test within that PSA range,
several options were proposed with a view
on increasing the specificity of the test and
avoiding unnecessary biopsies, which oc-
curs approximately 75% of the cases.
In the present study, the profiles of pa-
tients submitted to prostate biopsy were
outlined, identifying variables that, in as-
sociation with PSA values ranging between
2.6 and 10.0 ng/ml, would increase its
specificity.
One observed that the prevalence of
cancer proportionally increased with age.
More than 65% of all prostate cancers will
be diagnosed in men above 65 years of
age(1,2), as observed in the present study, in
which 72% of the patients with cancer were
65 years old or older.
As prostate volume was analyzed, one
could observe that, in patients with cancer,
the prostate volumes (41.4 cm3) were, on
average, smaller than in those patients with
negative results for cancer (59.9 cm3). Such
data is corroborated by studies in which
prostates with small volume, suspicious at
digital rectal examination and in patients
with elevated or intermediate PSA levels,
are significantly associated with anatomo-
pathological evidences of adenocarci-
noma(4,11)
.
Prostate specific antigen (PSA) was first
isolated by Wang in 1979(12). It is produced
by both normal and neoplastic prostatic
cells, and its serum concentration is signifi-
cantly related to prostate cancer volume(3,6).
The PSA levels are objective and easily
reproducible(6). According to some studies,
patients with PSA levels below 4.0 ng/ml
are considered as at low risk for prostate
adenocarcinoma(13,14). In this case, values
< 4.0 ng/ml would be considered as normal
and the interval between 4.1 and 10.0 ng/
ml would be the doubtful or intermediate
interval. In the present study, 17% of the
patients presented PSA levels < 4.0 ng/ml,
and of those patients, 11% presented results
Figure 3. Chart with the Gleason classification at different prostate zones.
Figure 2. Comparison between the ROC curves for the 0.15 ng/ml/cc and 0.09 ng/ml/cc cutoff points.
By analyzing the neoplasia location and
the grading attributed by the pathologist
according to the Gleason classification, a
comparative analysis of such data could be
carried out. The result is shown at a chart
(Figure 3), in which one observes that no
significant difference was found between
the location of the neoplasia manifestation
and its malignancy grade.
DISCUSSION
The present study evaluating the profile
of patients submitted to prostate biopsies
highlights the importance of PSAD and its
impact on the reduction of the number of
unnecessary prostate biopsies, with their
consequential complications and costs.
There is a widespread consensus that
the PSA level testing is the best available
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positive for cancer. Such values are simi-
lar to data reported in other studies(15,16),
which have demonstrated a lower preva-
lence of cancer at the 2.6 to 4.0 ng/ml PSA
level range. On the other hand, at the 4.1
to 10.0 ng/ml PSA level range, correspond-
ing to 83% of the patients, the prevalence
of cancer reached 32.1%.
The authors observed that the mean
PSA value in the individuals with cancer
was 8.9 ng/ml, which is higher than 6.1 ng/
ml found in the individuals with results
negative for cancer. In spite of the fact that
the present study comprised a range of re-
sults that can be considered as intermediate,
in which all the patients are suspicious for
cancer, a higher mean PSA concentration
was observed in individuals with cancer, a
fact corroborated by other studies(13,16).
In 1992, Benson et al.(7) introduced the
PSAD concept as a method to increase the
PSA testing specificity, by dividing the to-
tal PSA value by the total prostate volume.
In studying 127 male patients, that analy-
sis proposed that, in spite of a group of
patients with similar intermediate PSA lev-
els, stratifying such values according to
prostate volume, would lead to a more sig-
nificant correlation with benign and malig-
nant processes, consequently reducing the
number of unnecessary biopsies, without
compromising the cancer detection. Al-
though some authors recognize the useful-
ness of PSAD in the differentiation be-
tween cancer and benign prostatic hyper-
plasia(11,17), others put its validity into ques-
tion(18,19), since this method alone, with the
recommended cutoff point of 0.15 ng/ml/
cc(7), has a sensitivity of approximately
60%. Some years later, Catalona et al.(6), in
a multicentric study with 773 men, sug-
gested that the PSAD value be lowered to
0.078ng/ml/cc, a value at which 95% of the
tumors would be detected. In the present
study, the patients with positive results for
cancer presented a mean PSAD value of
0.31 ng/ml/cc, while those with negative
results presented a mean PSAD value of
0.10 ng/ml/cc. If a PSAD cutoff point of
0.15 ng/ml/cc was utilized, the test sensi-
tivity would have been 65%, a low value
for a screening test. On the other hand, by
reducing such value to 0.09 ng/ml/cc, a
sensitivity similar to the value of 83% ob-
tained by Djavan et al.(20) would be found.
The specificity with these two values
would be similar. For a cancer screening
test, the high sensitivity (83.8%) and PPV
(92.0%) of the method should be priori-
tized. Thus, by choosing the cutoff point of
0.09 ng/ml/cc, the number of false negative
results would be reduced. In the study with
the PSA level between 2.6 and 10.0 ng/ml,
the number of patients submitted to unnec-
essary biopsy corresponded to 71.4% of all
procedures. With the utilization of PSAD,
this percentage could be reduced to less
than 30% for both cutoff points.
As the LR was utilized, values for LR+
that indicate a moderate change in the prob-
ability of cancer at both cutoff points were
found. However, for LR–, the authors
found values indicating a small change in
the probability of cancer for the cutoff
point of 0.15 ng/ml/cc (0.40) and moder-
ate change for the 0.09 ng/ml/cc (0.22)
cutoff point. Taking this evaluation into
consideration, the 0.09 ng/ml/cc cutoff
point would be the most appropriate.
The anatomopathological results posi-
tive for prostate cancer were analyzed by
pathologists who utilized the Gleason clas-
sification for malignancy. For being an
analysis that can be made in all fragments,
it would be possible to find out where the
more and less differentiated tumors oc-
curred. In the present study, no significant
difference was observed between the loca-
tion of the neoplasias and their malignancy
grading.
In the present study, it was observed that
the patients with prostate cancer were on
average older, with higher PSA and PSAD
values, and had a smaller prostate volume.
The present data indicate a good PSAD
accuracy in the prediction of prostate can-
cer, with the potential of substantially re-
ducing the number of unnecessary biop-
sies.
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